A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

Summary

This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians' choice of treatment.

Timeline

Start

2021-03-17

Primary completion

2026-09

Completion

2026-09

Publications

• Grosicki S, Yimer H, Ayala R, Chen S, Liu H, Boyer F, Guglielmelli P, Brociner M, Sportoletti P, Mikala G, Tsirigotis P, Zhang J, Mark T, Chai Y, Ellero A, Lucchesi A. Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study. EJHaem. 2026 Jun 1;7(3):e70301. doi: 10.1002/jha2.70301. eCollection 2026 Jun.

Drugs

Indications